Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.79 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.79 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.79 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14516215 | 1.00 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL16922134 | 1.00 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL8374709 | 1.00 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Water SCHEMBL2443250 | 0.99 | OPRM1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Hydrochloric Acid SCHEMBL27503745 | 0.99 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL8412616 | 0.94 | OPRD1 (0.75) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL12082104 | 0.93 | OPRM1 (0.80) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL27268268 | 0.93 | OPRD1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL6266395 | 0.92 | OPRD1 (0.67) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Diacetylmorphine SCHEMBL6566145 | 0.91 | OPRM1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414604-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2023-12-28 | — | — | US | claimed |
| US-20200345720-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2020-11-05 | — | — | US | claimed |
| US-20190167665-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2019-06-06 | — | — | US | claimed |
| CN-108593828-A | Blood plasma prepares the detection method of drug and toxic content in card | 李水军 | 2018-09-28 | — | — | CN | claimed |
| CN-107935966-A | A kind of production method of dimethomorph | 江苏恒隆作物保护有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-107626210-A | A kind of high molecular polymer microporous barrier and preparation method thereof | 华南理工大学 | 2018-01-26 | — | — | CN | claimed |
| CN-106694049-A | Methyl acetate catalyst system and application | 西南化工研究设计院有限公司 | 2017-05-24 | — | — | CN | claimed |
| CN-106687540-A | Low toxicity solvent system for polyamideimide and polyamide amic acid resin coating | 富士胶片亨特化学制品美国有限公司 | 2017-05-17 | — | — | CN | claimed |
| CN-104610196-B | A kind of method synthesizing N-acetyl morphine | 烟台大学 | 2016-08-24 | — | — | CN | claimed |
| US-20160175297-A1 | Morphine Formulations | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2016-06-23 | — | — | US | claimed |
| EP-1053238-A4 | THERAPEUTIC COMPOUNDS | UNIV MONASH (AU) | 2003-09-03 | — | — | EP | claimed |
| WO-2003014122-A1 | DERIVATIVES OF MORPHINE-LIKE OPIOID COMPOUNDS | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2003-02-20 | — | — | WO | claimed |
| EP-0767663-B1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORP (US) | 2002-04-03 | — | — | EP | claimed |
| CN-1327158-A | Establishment of anti-morphine single anti-cell strain and method for producing double-side morphine test paper | UNIV BEIJING (CN) | 2001-12-19 | — | — | CN | claimed |
| EP-1053238-A1 | THERAPEUTIC COMPOUNDS | MONASH UNIVERSITY (AU) | 2000-11-22 | — | — | EP | claimed |
| WO-1999038869-A1 | THERAPEUTIC COMPOUNDS | MONASH UNIVERSITY (AU) | 1999-08-05 | — | — | WO | claimed |
| EP-0767663-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| US-5593695-A | Morphine therapy | ALZA CORPORATION (US) | 1997-01-14 | — | — | US | claimed |
| WO-1996000066-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1996-01-04 | — | — | WO | claimed |
| US-5460826-A | Morphine therapy | ALZA CORPORATION (US) | 1995-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345720-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
| US-20190167665-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
| US-20230414604-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
| US-20160175297-A1 | Morphine Formulations | OPRM1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.